Committed To Holistic Growth

Divi's Laboratories has grown to be among the top generic drug makers in the country focused on active pharmaceutical ingredients (API) and intermediates. The company not only commands 60-85 per cent global market share in generic naproxen, dextromethorphan and gabapentin APIs today, it also produces nutraceuticals as well as undertakes custom manufacturing for Big Pharma.

 The company owes its success to the vision and leadership of its founder and managing director Murali K. Divi. US-trained Divi first began by launching Divi's Research Centre in the early 1990s with the idea of developing commercial processes for the manufacture of APIs and intermediates. In 1994, he changed his company’s name to Divi's Laboratories, signalling his intent to enter the API and intermediates manufacturing market.

 The company’s success is also reflected in its sound financials. In FY22, total income stood at Rs 8,991.08 crore, while consolidated total revenue was Rs 9,074 crore as against Rs 7,032 crore during the previous year, reflecting a growth of 29 per cent. Profit after tax (PAT) for the year amounted to Rs 2,960 crore compared to Rs 1,984 crore recorded last year, reflecting a growth of 49 per cent.

 "The year had been challenging with several headwinds and against this backdrop, our results for the year demonstrate our execution prowess, agility, strategic clarity and the strength of supply chain. Our core investment for the past two years on debottlenecking, capacity expansion and backward integration strength helped us achieve scale and de-risk external starting material dependence," Divi said in his address to the shareholders.

 Green Commitment

During FY2022, apart from creating additional capacities for its pipeline products and new capacities for emerging custom synthesis projects, the company also upgraded its utility infrastructure, which also included environment management. “We strive to create brand value by adopting sustainable practices and implementing green chemistry principles,” Divi adds.

As an industry leader and a responsible enterprise, Divi’s Labs served the communities around its manufacturing facilities in several ways by enhancing the village infrastructure, providing safe drinking water, empowering women and improving public healthcare.

 Future Focused

As the company entered a new financial year, it was better prepared to handle the evolving demand, continuous market volatility and an uncertain economic environment, he added. “At Divi’s, we aim to exceed the internal benchmark so that we can consistently deliver value to our customers, and also perform as a dependable supplier,” said Divi.

The company’s focus will remain on continuous process innovation and green chemistry implementation to further establish Divi's as a strong, sustainable organisation and deliver value-added performance. “We will continue to strive for leadership through chemistry and be the most reliable supplier of high-quality API’s while creating value for all our stake holders,” said Divi.

Over the past decade, Divihas focused on several corporate social responsibility programmes and impacted the lives of lakhs of people in Andhra Pradesh and Telangana. With a commitment to make meaningful change a reality, Divi’s continues to undertake varied initiatives aimed at improving lives.

Divi’s has supported hundreds of government schools in Telangana and Andhra Pradesh to improve their infrastructure and provide a conducive environment for learning and social development of children.

Since 2014, Divi's has installed adequate safe water stations in Telangana and Andhra Pradesh, thereby providing safe drinking water to lakhs of people.